Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming
New York, January 28, 2026, 11:16 a.m. ET — Regular session Pfizer (PFE) shares were down 1.7% at $26.06 in late morning trade on Wednesday after the U.S. Centers for Medicare & Medicaid Services added its arthritis drug Xeljanz to the next round of Medicare drug price negotiations. CMS said the talks will run in 2026, with negotiated prices slated to take effect on Jan. 1, 2028, and companies facing a Feb. 28 deadline to sign participation agreements. (CMS) The selection lands at an awkward time for big drugmakers. Investors have been trying to map out how much the next